U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE...
Brain
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads...
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate...
Orphalan announces enrolment of the first five patients in the International Wilson’s Disease Patient Registry (“iWD Registry”)
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”) World’s first global...
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
Renowned neuroscience leader to further long-term clinical research strategy and external collaborationsCAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion...
Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint
•Company’s novel drug development program AM-411 builds on positive animal data •Treatments for rheumatoid arthritis represent the second largest therapeutic...
Neuronetics and Alleviant Health Centers Announce Exclusive Partnership
Partnership Will Bring Non-drug NeuroStar® Advanced Therapy for Mental Health to Thousands More Patients MALVERN, Pa., July 25, 2022 (GLOBE...
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer’s Disease
Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings,...
Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19 Showing Significant Reduction in Inflammatory and Neuroinflammatory Markers and Improved Clinical Outcomes
– Data showed OP-101 delivered intravenously may have the potential to treat systemic inflammation and neuronal injury, reducing morbidity and...
Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapiesTOKYO,...
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Commission for Upstaza™ – First Disease-Modifying Treatment for AADC Deficiency
First Gene Therapy Approved for Direct Infusion into the Brain will be Administered with ClearPoint’s SmartFlow® Neuro CannulaSOLANA BEACH, Calif.,...
Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases On track to...
NeuroPace to Report Second Quarter 2022 Financial Results on August 11, 2022
MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on...
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022 Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Division sales...
Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)
CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation...
Nexstim Receives an NBS System Order from a Finnish Customer
Press release, Helsinki, 19 July 2022 at 10 AM (EET) Nexstim Receives an NBS System Order from a Finnish Customer...
Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 Alzheimer’s Association International Conference (AAIC)
– Scientific collaborators at Stanford University will present preclinical data on the sensitivity of OP-801 in comparison to TSPO-PET for...
George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer
Building on strong foundations to take Small Pharma through development to commercial success Peter Rands to take on role as...
Small Pharma Reports Fiscal First Quarter 2023 Highlights
Progress continues apace with multiple trials expected to enter clinic later this year First US patent granted LONDON, July 15,...